RxDoctor Payments Data

Howard Cohen, MD

Internal Medicine · Camp Hill, PANPI 1790786499

Payments from drug & device makers

$965in general payments, 2019–2025

Across 60 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$495
  • Verona Pharma, Inc.$157
  • Novo Nordisk$51
  • E.r. Squibb & Sons, L.L.C.$44
  • Johnson & Johnson$30
  • Biotronik Inc.$28
  • plus $160 from 9 others

What the payments were for

  • Food & beverage$965100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$965 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$449,323
Medicare patients
382
Services billed
4,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$176,182
JardianceEmpagliflozin45$62,319
OzempicSemaglutide23$29,052
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$22,076
EntrestoSacubitril/Valsartan15$20,819
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$17,443
TrulicityDulaglutide14$15,530
InvokanaCanagliflozin16$15,318
Novolog FlexpenInsulin Aspart19$11,053
JanuviaSitagliptin Phosphate12$7,890
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$7,541
Breo ElliptaFluticasone/Vilanterol12$6,901
Atorvastatin Calcium403$6,780
TradjentaLinagliptin12$5,823
MyrbetriqMirabegron13$5,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$176,182158 claims
Novo NordiskOzempic$51$29,05223 claims
NovartisEntresto$21$20,81915 claims
Lilly USA, LLCTrulicity$25$15,53014 claims
Johnson & JohnsonInvokana$30$15,31816 claims
AbbVieSynthroid$15$2,01448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Camp Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →